741 related articles for article (PubMed ID: 25875940)
1. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
Othman AA; Dutta S
Br J Clin Pharmacol; 2014 Jul; 78(1):94-105. PubMed ID: 24433449
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
Nyholm D; Odin P; Johansson A; Chatamra K; Locke C; Dutta S; Othman AA
AAPS J; 2013 Apr; 15(2):316-23. PubMed ID: 23229334
[TBL] [Abstract][Full Text] [Related]
4. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
[TBL] [Abstract][Full Text] [Related]
5. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
[TBL] [Abstract][Full Text] [Related]
6. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
[TBL] [Abstract][Full Text] [Related]
7. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
8. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
Buongiorno M; Antonelli F; Cámara A; Puente V; de Fabregues-Nebot O; Hernandez-Vara J; Calopa M; Pascual-Sedano B; Campolongo A; Valldeoriola F; Tolosa E; Kulisevsky J; Martí MJ
Parkinsonism Relat Disord; 2015 Aug; 21(8):871-6. PubMed ID: 26003410
[TBL] [Abstract][Full Text] [Related]
9. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
[TBL] [Abstract][Full Text] [Related]
10. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
[TBL] [Abstract][Full Text] [Related]
11. [Levodopa-carbidopa intestinal gel in the treatment of patients with Parkinson disease: results of a 12-month open study].
Skoromets AA; Odinak MM; Yakupov EZ; Litvinenko IV; Zalyalova ZA; Timofeeva AA; Kirtaev SY; Bogdanov RR; Agafina AS; Chatamra K; Robieson W; Benesh J; Latypova GR; Ershova MV; Illarioshkin SN
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):22-31. PubMed ID: 28374689
[TBL] [Abstract][Full Text] [Related]
12. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.
Fernandez HH; Vanagunas A; Odin P; Espay AJ; Hauser RA; Standaert DG; Chatamra K; Benesh J; Pritchett Y; Hass SL; Lenz RA
Parkinsonism Relat Disord; 2013 Mar; 19(3):339-45. PubMed ID: 23287001
[TBL] [Abstract][Full Text] [Related]
13. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
Regidor I; Santos-García D; Catalán MIJ; Puente V; Valldeoriola F; Grandas F; Mir P; Parra JC; Arbelo JM
J Parkinsons Dis; 2019; 9(1):173-182. PubMed ID: 30562907
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
[TBL] [Abstract][Full Text] [Related]
15. Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
Bohlega S; Abou Al-Shaar H; Alkhairallah T; Al-Ajlan F; Hasan N; Alkahtani K
Eur Neurol; 2015; 74(5-6):227-36. PubMed ID: 26618531
[TBL] [Abstract][Full Text] [Related]
16. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Udd M; Lyytinen J; Eerola-Rautio J; Kenttämies A; Lindström O; Kylänpää L; Pekkonen E
Brain Behav; 2017 Jul; 7(7):e00737. PubMed ID: 28729942
[TBL] [Abstract][Full Text] [Related]
17. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
Antonini A; Poewe W; Chaudhuri KR; Jech R; Pickut B; Pirtošek Z; Szasz J; Valldeoriola F; Winkler C; Bergmann L; Yegin A; Onuk K; Barch D; Odin P;
Parkinsonism Relat Disord; 2017 Dec; 45():13-20. PubMed ID: 29037498
[TBL] [Abstract][Full Text] [Related]
18. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
[TBL] [Abstract][Full Text] [Related]
19. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
Fabbri M; Zibetti M; Beccaria L; Merola A; Romagnolo A; Montanaro E; Ferreira JJ; Palermo S; Lopiano L
Eur J Neurol; 2019 Mar; 26(3):490-496. PubMed ID: 30347489
[TBL] [Abstract][Full Text] [Related]
20. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
